Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review
Suzanne A Ligthart1, Eric P Moll van Charante1, Willem A Van Gool2, Edo Richard2
1Department of General Practice, 2Department of Neurology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Background: Over the last decade, evidence has accumulated that vascular risk factors increase the risk of Alzheimer disease (AD). So far, few randomized controlled trials have focused on lowering the vascular risk profile to prevent or postpone cognitive decline or dementia.
Objective: To systematically perform a review of randomized controlled trials (RCTs) evaluating drug treatment effects for cardiovascular risk factors on the incidence of dementia or cognitive decline.
Selection criteria: RCTs studying the effect of treating hypertension, dyslipidemia, hyperhomocysteinemia, obesity, or diabetes mellitus (DM) on cognitive decline or dementia, with a minimum follow-up of 1 year in elderly populations.
Outcome measure: Cognitive decline or incident dementia.
Main results: In the identified studies, dementia was never the primary outcome. Statins (2 studies) and intensified control of type II DM (1 study) appear to have no effect on prevention of cognitive decline. Studies on treatment of obesity are lacking, and the results of lowering homocysteine (6 studies) are inconclusive. There is some evidence of a preventive effect of antihypertensive medication (6 studies), but results are inconsistent.
Conclusion: The evidence of a preventive treatment effect aimed at vascular risk factors on cognitive decline and dementia in later life is scarce and mostly based on secondary outcome parameters. Several important sources of bias such as differential dropout may importantly affect interpretation of trial results.
Keywords: cardiovascular risk factors, cognitive decline, dementia, prevention
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
Readers of this article also read:
Lumbosacral plexus delineation, dose distribution, and its correlation with radiation-induced lumbosacral plexopathy in cervical cancer patients
Tunio M, Al Asiri M, Bayoumi Y, Abdullah O Balbaid A, AlHameed M, Gabriela SL, Amir O Ali A
Published Date: 23 December 2014
Ex vivo and in vivo evaluation of an ultrasonic device for precise dissection, coagulation, and transection
Bertke BD, Scoggins PJ, Welling AL, Widenhouse TV, Chen C, Kallakuri S, Cavanaugh JM, Clymer JW, Amaral JF
Published Date: 18 December 2014
Renal interstitial fibrosis induced by high-dose mesoporous silica nanoparticles via the NF-κB signaling pathway
Chen X, Zhouhua W, Jie Z, Xinlu F, Jinqiang L, Yuwen Q, Zhiying H
Published Date: 18 December 2014
Chen DZ, Tang QS, Li XD, Zhou XJ, Zang J, Xue WQ, Xiang JY, Guo CQ
Published Date: 14 September 2012
Jabir NR, Tabrez S, Ashraf GM, Shakil S, Damanhouri GA, Kamal MA
Published Date: 9 August 2012
Assessment of ocular hypotensive effect and safety 12 months after changing from an unfixed combination to a latanoprost 0.005% + timolol maleate 0.5% fixed combination
Inoue K, Okayama R, Higa R, Wakakura M, Tomita G
Published Date: 18 April 2012
Farazuddin M, Sharma B, Khan AA, Joshi B, Owais M
Published Date: 5 January 2012
Nelson DA, Ruf A, Oaknin J, Burgansky-Eliash Z, Barash H, Izhaky D, Loewenstein A, Barak A, Bartov E, Rock T, Grinvald A
Published Date: 15 September 2011
Insulin resistance and plasma triglyceride level are differently related to cardiac hypertrophy and arterial stiffening in hypertensive subjects
Liliana Legedz, Giampiero Bricca, Pierre Lantelme, Marie-Odile Rial, Pierre Champomier, Madeleine Vincent, Hugues Milon
Published Date: 2 March 2006
Fasting serum triglyceride and high-density lipoprotein cholesterol levels in patients intended to be treated for dyslipidemia
Genovefa D Kolovou, Katherine Anagnostopoulou, Nektarios D Pilatis, Klelia D Salpea, Ioannis S Hoursalas, Ilias Petropoulos, Helen I Bilianou, Dennis V Cokkinos
Published Date: 29 January 2005